Corteva, Inc. logo CTVA - Corteva, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY
0
BUY 23
HOLD 12
SELL 2
STRONG
SELL
0
| PRICE TARGET: $95.38 DETAILS
HIGH: $103.00
LOW: $86.00
MEDIAN: $96.00
CONSENSUS: $95.38
UPSIDE: 11.04%
AlphaVal

AlphaVal

Deterministic, archetype-aware fair value

Cyclical & Capital-Intensive 80% confidence

Primary model: Normalized Earnings × Cycle Multiple

Valuation Signal Overvalued Strong
Trading 472.3% above fair value
Current Price $85.90
Bear Case $11.06 87.1% downside ($11.06 - $85.90) / $85.90 = -87.1% $1.58 × 7x
Fair Value $15.01 82.5% downside ($15.01 - $85.90) / $85.90 = -82.5% $1.58 × 10x
Bull Case $18.96 77.9% downside ($18.96 - $85.90) / $85.90 = -77.9% $1.58 × 12x

Adjust Assumptions

9.5x
1.58$

Key Value Driver

Through-cycle normalized EPS ($1.58)

Implied Market Multiple 54.4x

Plain-Language Summary

Using 7-year normalized EPS of $1.58 at a 10x cycle multiple, the base-case value is $15.01 per share. P/TBV cross-check: 10.7x.

Analyst Consensus (External Reference)

Never blended into the bear/base/bull estimates above -- shown only as an outside comparison.

Average Target (37 analysts) $95.38
Analyst Range $86.00 – $103.00
Divergence from AlphaVal 84%

Warnings

Price-to-book value of 10.7x is above the normal range for this type of business (0.7x-2.0x). The stock may already price in a strong cycle.
Wall Street's average price target is $95.38 (from 37 analysts). Our estimate is 84% below the consensus -- consider that gap carefully.

Key Risks

  • Standard 10-year DCF produces unreliable terminal values for cyclicals
  • 'Cheap' P/E at cycle peak is the most common value trap — normalize first
  • Captive finance subsidiaries have different risk profiles from manufacturing